A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT06109272 · LIVIGNO-2 Phase 2/3Active, not recruiting
- Lead sponsor
- AbbVie (Industry)
- Enrollment
- 89 (actual)
- Start date
- 11 Jan 2024
- Primary completion
- Jan 2027 (estimated)
- Study completion
- 1 Jan 2027
- Last update posted
- 22 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Sequential
- Masking
- None
- Arms
- 6
Interventions
- Livmoniplimab Drug
- Budigalimab Drug
- Durvalumab Drug
- Atezolizumab Drug
- Bevacizumab Drug
- Tremelimumab Drug
Conditions and primary outcome
- Hepatocellular Carcinoma
Primary outcome
Stage 1: Best Overall Response (BOR) per Investigator (Through Study Completion, Up to Approximately 56 Months); Stage 2: Overall Survival (OS) (Through Study Completion, Up to Approximately 56 Months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06109272.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06109272 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.